Categories AlphaGraphs, Health Care
Infographic: Abbott (ABT) reports Q2 2020 earnings
Weakness in medical devices unit hurt overall results in Q2
Abbott Laboratories (NYSE: ABT) reported second-quarter financial results before the regular trading hours on Thursday. Revenue for the quarter fell 8% to b $7.3 billion, while adjusted EPS declined 31% to $0.57.
However, the results were stronger than street projections, which sent the stock up 1% during pre-market hours. The stock has gained 11% since the beginning of this year.
The largest Medical Devices unit was the worst hit, where sales dropped 21%, as hospitals postponed various surgeries to cater to COVID patients. Earlier today, rival Johnson & Johnson (NYSE: JNJ) also reported a massive 35% decline in quarterly earnings, hurt by weakness in the medical devices segment.
Past performance
Also read: Abbott (ABT) could make a new 52-week high after upbeat Q2 results and rosier outlook
Most Popular
COVID-19 drove retailers up the digital path years ahead than anticipated
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Snowflake (SNOW) creates a record as the most successful software IPO ever; stock more than doubles
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
Adobe (ADBE) sees new tailwinds as virtual shift gathers steam
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related